The State of Biosimilars in 2023

The beginning of 2023 saw a much anticipated launch of the first Humira® (adalimumab) biosimilar Amjevita™. (adalimumab-atto), with at least seven additional ...

A Promise Unfulfilled: The State of Biosimilars - Pharmacy Times

The promise seemed clear: new biosimilars entering the market would finally lead to genuine competition that would drive down prices and improve access for ...

In this report, the current state of the biologics market in the United States and share of the market facing biosimilar competition are assessed.

January 2023 represents a watershed moment for the biosimilars market as the first adalimumab biosimilar is finally expected to launch.

2023 U.S. Generic and Biosimilar Medicines Savings Report

Up from $119 billion and $178 billion in 2021, generics and biosimilars continue to provide critical savings throughout the health-care system and are ...

Biosimilar Product Information | FDA

This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access ...

The evolution of biosimilars in the United States - Milliman

Stelara, one of the selected Part D drugs for 2026, has a biosimilar, Wezlana, that was approved by the FDA on. October 31, 2023.43 However, the ...

News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big “deluge” in biosimilars, ...

Now Trending: Biosimilars - IQVIA

Celltrion's Yuflygma received FDA approval in June 2023 as the 9th adalimumab biosimilar (i.e., Humira biosimilar) and is expected to launch in ...

Biosimilars Action Plan - FDA

On March 2, 2023, FDA and the Federal Trade Commission (FTC) released an educational resource for consumers about biosimilars and ...

Generic and Biosimilar Medicines Save $445 Billion in 2023

AAM's annual savings report reveals that the use of Food and Drug Administration (FDA) approved generic and biosimilar medicines created $445 ...

Contributor: The US Biosimilar Market Outlook for 2023

Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to ...

Current and Future State of Biosimilars - Matrix Global Advisors

Finally, the blockbuster immunology biologic Humira (adalimumab) represents the newest biosimilar market, with the first biosimilar launched in ...

Top 5 Most-Read Biosimilar Articles in 2023

In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching.

Biosimilars Report | Cardinal Health

Read our analysis of changing perspectives of some of the most disruptive biosimilars launched in the areas of immunology and ophthalmology in the 2023 ...

There are currently 62 biosimilars approved by the US Food and Drug Administration (FDA). The most recent biosimilar approval was Imuldosa (ustekinumab-srlf) ...

When biosimilar copies of AbbVie's top-selling drug Humira arrived in 2023, the impact was hard to see. Now, that's beginning to change as a few ...

What 2023 Has Taught Us About Biosimilar Adoption

The complexities of the US health care market, low awareness of biosimilars, and a reluctance by health care practitioners (HCPs) and patients ...

Data Snapshot: Biosimilar Cost and Use Trends in Medicare Part B

In September 2023, OIG issued Biosimilars Have Lowered Costs for Medicare Part B and Enrollees, but Opportunities for Substantial Spending ...

We will review the past, present, and future of biosimilars. Specifically, recount the historic impact US healthcare savings, spotlight the long ...